WinstonWınston
Vimta Labs Limited logo

Vimta Labs Limited

VIMTALABS.BO
56
Medical - Diagnostics & Research · Healthcare
Price
₹559.50
-4.85 (-0.86%)
Market Cap
₹25.52B
Exchange
Bombay Stock Exchange
Winston Score
56
Winston is curious
A decent business — some strong pillars, some weaker.

Share count rising — dilution

+99.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 22.6M (2022) → 45.1M (2026)

Vimta Labs Limited is an Indian testing and research company that checks whether medicines, food, and environmental samples are safe and meet quality standards. Its main customers are pharmaceutical companies, food manufacturers, and government agencies that need certified lab results before they can sell or approve products. Vimta is one of India's established independent contract testing laboratories, accredited by multiple national and international bodies.

The company earns money by charging fees each time a client sends samples for testing, analysis, or clinical research services — there are no subscriptions, just service contracts and project-based work. Vimta operates primarily in India, with its main facilities in Hyderabad, and generates revenue largely from domestic pharmaceutical clients, though export-oriented drug makers also use its services to meet global regulatory requirements. Its key growth driver is the continued expansion of India's pharmaceutical manufacturing sector, which increases demand for third-party testing; the main risk is pricing pressure and competition from larger global contract research organizations entering the Indian market.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+15.7% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+15.1% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$10M/ year

0.3% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

65.8%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$747M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Vimta Labs Limited is a rare growth stock that's already generating positive cash flow while growing at 16%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
40.7%
Healthy — 40.7% gross margin
Operating Margin
24.4%
Excellent — 24.4% operating margin
ROCE
5.8%
Weak — 5.8% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+14.8%
Fast-growing sales (14.8% YoY)
EPS YoY
-4.6%
Earnings shrinking (-4.6% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
97%
Turns 97% of profit into real cash
FCF Margin
6.7%
Modest free cash flow (6.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.01
Conservative — low debt load (0.01)
Interest Cover
75.77x
Comfortably covers interest (75.8x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
32.4x
Pricey — P/E 32.4

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+3.4
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (32.4 → 29.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
0.34%
Small dividend — 0.34% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
+0.0%
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial